Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 April 2015Next earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 22:50:40 GMTDividend
Analysts recommendations
Institutional Ownership
BPMC Latest News
LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / June 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / June 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / June 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
What type of business is Blueprint Medicines?
Blueprint Medicines Corporation is a precision therapy company specializing in genomic cancer diseases, rare diseases, and cancer immunotherapy. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts. Blueprint Medicines Corporation is developing the following drugs: avapritinib - for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263 - an oral potent inhibitor for the treatment of indolent SM and other mast cell diseases; fisogatinib - an oral potent inhibitor currently in phase I clinical trials for the treatment of hepatocellular carcinoma and other drugs for the treatment of rare genomic and tumor diseases.
What sector is Blueprint Medicines in?
Blueprint Medicines is in the Healthcare sector
What industry is Blueprint Medicines in?
Blueprint Medicines is in the Biotechnology industry
What country is Blueprint Medicines from?
Blueprint Medicines is headquartered in United States
When did Blueprint Medicines go public?
Blueprint Medicines initial public offering (IPO) was on 30 April 2015
What is Blueprint Medicines website?
https://www.blueprintmedicines.com
Is Blueprint Medicines in the S&P 500?
No, Blueprint Medicines is not included in the S&P 500 index
Is Blueprint Medicines in the NASDAQ 100?
No, Blueprint Medicines is not included in the NASDAQ 100 index
Is Blueprint Medicines in the Dow Jones?
No, Blueprint Medicines is not included in the Dow Jones index
When does Blueprint Medicines report earnings?
The next expected earnings date for Blueprint Medicines is 02 August 2024